Literature DB >> 17201419

Partial retro-inverso, retro, and inverso modifications of hydrazide linked bifunctional peptides for opioid and cholecystokinin (CCK) receptors.

Yeon Sun Lee1, Richard S Agnes, Peg Davis, Shou-wu Ma, Hamid Badghisi, Josephine Lai, Frank Porreca, Victor J Hruby.   

Abstract

Partially modified retro-inverso, retro, and inverso isomers of hydrazide linked bifunctional peptides were designed, synthesized, and evaluated for bioactivities at delta/mu opioid receptors and CCK-1/CCK-2 receptors. All modifications of the CCK pharmacophore moiety affected bioactivities for the CCK-1 and CCK-2 receptors (up to 180-fold increase in the binding affinity with higher selectivity) and for the delta and mu opioid receptors. The results indicate that the opioid and CCK pharmacophores in one molecule interact with each other to induce topographical changes for both pharmacophores.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17201419      PMCID: PMC2365893          DOI: 10.1021/jm061268p

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  12 in total

1.  Design of novel peptide ligands which have opioid agonist activity and CCK antagonist activity for the treatment of pain.

Authors:  V J Hruby; R S Agnes; P Davis; S-W Ma; Y S Lee; T W Vanderah; J Lai; F Porreca
Journal:  Life Sci       Date:  2003-06-27       Impact factor: 5.037

Review 2.  Cholecystokinin/opioid interactions.

Authors:  Z Wiesenfeld-Hallin; G de Araúja Lucas; P Alster; X J Xu; T Hökfelt
Journal:  Brain Res       Date:  1999-11-27       Impact factor: 3.252

3.  Tetrapeptide CCK agonists: structure-activity studies on modifications at the N-terminus.

Authors:  R L Elliott; H Kopecka; M J Bennett; Y K Shue; R Craig; C W Lin; B R Bianchi; T R Miller; D G Witte; M A Stashko
Journal:  J Med Chem       Date:  1994-01-21       Impact factor: 7.446

Review 4.  CCK-B receptor: chemistry, molecular biology, biochemistry and pharmacology.

Authors:  F Noble; B P Roques
Journal:  Prog Neurobiol       Date:  1999-07       Impact factor: 11.685

5.  Cholecystokinin-B receptor antagonists attenuate morphine dependence and withdrawal in rats.

Authors:  L Lu; M Huang; Z Liu; L Ma
Journal:  Neuroreport       Date:  2000-03-20       Impact factor: 1.837

6.  Evidence for the neuropeptide cholecystokinin as an antagonist of opiate analgesia.

Authors:  P L Faris; B R Komisaruk; L R Watkins; D J Mayer
Journal:  Science       Date:  1983-01-21       Impact factor: 47.728

7.  Immunostimulation by a partially modified retro-inverso-tuftsin analogue containing Thr1 psi[NHCO](R,S)Lys2 modification.

Authors:  A S Verdini; S Silvestri; C Becherucci; M G Longobardi; L Parente; S Peppoloni; M Perretti; P Pileri; M Pinori; G C Viscomi
Journal:  J Med Chem       Date:  1991-12       Impact factor: 7.446

8.  Caerulein and cholecystokinin suppress beta-endorphin-induced analgesia in the rat.

Authors:  S Itoh; G Katsuura; Y Maeda
Journal:  Eur J Pharmacol       Date:  1982-06-04       Impact factor: 4.432

9.  Potentiation of opiate analgesia and apparent reversal of morphine tolerance by proglumide.

Authors:  L R Watkins; I B Kinscheck; D J Mayer
Journal:  Science       Date:  1984-04-27       Impact factor: 47.728

10.  Neural basis for the hyperalgesic action of cholecystokinin in the rostral ventromedial medulla.

Authors:  Mary M Heinricher; Miranda J Neubert
Journal:  J Neurophysiol       Date:  2004-05-19       Impact factor: 2.714

View more
  11 in total

1.  Modulation of cell surface expression of nonactivated cholecystokinin receptors using bivalent ligand-induced internalization.

Authors:  Kaleeckal G Harikumar; Eyup Akgün; Philip S Portoghese; Laurence J Miller
Journal:  J Med Chem       Date:  2010-04-08       Impact factor: 7.446

2.  Design and synthesis of trivalent ligands targeting opioid, cholecystokinin, and melanocortin receptors for the treatment of pain.

Authors:  Yeon Sun Lee; Steve Fernandes; Vinod Kulkarani; Alexander Mayorov; Peg Davis; Shou-wu Ma; Kathy Brown; Robert J Gillies; Josephine Lai; Frank Porreca; Victor J Hruby
Journal:  Bioorg Med Chem Lett       Date:  2010-05-24       Impact factor: 2.823

Review 3.  Investigational peptide and peptidomimetic μ and δ opioid receptor agonists in the relief of pain.

Authors:  Aswini Kumar Giri; Victor J Hruby
Journal:  Expert Opin Investig Drugs       Date:  2013-12-13       Impact factor: 6.206

Review 4.  Bi- or multifunctional opioid peptide drugs.

Authors:  Peter W Schiller
Journal:  Life Sci       Date:  2009-03-11       Impact factor: 5.037

5.  An APP inhibitory domain containing the Flemish mutation residue modulates gamma-secretase activity for Abeta production.

Authors:  Yuan Tian; Bhramdeo Bassit; Deming Chau; Yue-Ming Li
Journal:  Nat Struct Mol Biol       Date:  2010-01-10       Impact factor: 15.369

6.  Synthesis and investigations of double-pharmacophore ligands for treatment of chronic and neuropathic pain.

Authors:  Ruben Vardanyan; Gokhale Vijay; Gary S Nichol; Lu Liu; Isuru Kumarasinghe; Peg Davis; Todd Vanderah; Frank Porreca; Josephine Lai; Victor J Hruby
Journal:  Bioorg Med Chem       Date:  2009-06-02       Impact factor: 3.641

7.  PK20, a new opioid-neurotensin hybrid peptide that exhibits central and peripheral antinociceptive effects.

Authors:  Patrycja Kleczkowska; Piotr Kosson; Steven Ballet; Isabelle Van den Eynde; Yuko Tsuda; Dirk Tourwé; Andrzej W Lipkowski
Journal:  Mol Pain       Date:  2010-12-06       Impact factor: 3.395

Review 8.  Novel Molecular Strategies and Targets for Opioid Drug Discovery for the Treatment of Chronic Pain.

Authors:  Keith M Olson; Wei Lei; Attila Keresztes; Justin LaVigne; John M Streicher
Journal:  Yale J Biol Med       Date:  2017-03-29

9.  The Effects of Side-Chain Configurations of a Retro-Inverso-Type Inhibitor on the Human T-Cell Leukemia Virus (HTLV)-1 Protease.

Authors:  Chiyuki Awahara; Daiki Oku; Saki Furuta; Kazuya Kobayashi; Kenta Teruya; Kenichi Akaji; Yasunao Hattori
Journal:  Molecules       Date:  2022-03-02       Impact factor: 4.411

10.  In Vivo, In Vitro and In Silico Studies of the Hybrid Compound AA3266, an Opioid Agonist/NK1R Antagonist with Selective Cytotoxicity.

Authors:  Joanna Matalińska; Piotr F J Lipiński; Piotr Kosson; Katarzyna Kosińska; Aleksandra Misicka
Journal:  Int J Mol Sci       Date:  2020-10-19       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.